Yes is a central mediator of cell growth in malignant mesothelioma cells

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1889-1893

  Sato, Ayami ^a   Sekine, Miki ^a   Virgona, Nantiga ^a   Ota, Masako ^a   Yano, Tomohiro ^a  

^a TOYO UNIVERSITY   (Japan)

Author keywords

catenin; Apoptosis; G1 arrest; Mesothelioma; Yes

Indexed keywords

BETA CATENIN; CYCLIN D; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INACTIVATION; ENZYME REPRESSION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; MITOSIS INHIBITION; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; BETA CATENIN; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MESOTHELIOMA; PROTO-ONCOGENE PROTEINS C-FYN; PROTO-ONCOGENE PROTEINS C-YES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SRC-FAMILY KINASES;

EID: 84866460554     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2010     Document Type: Article

References (26)

1. Carbone M, Kratzke RA and Testa JR: The pathogenesis of mesothelioma. Semin Oncol 29: 2-17, 2002. (Pubitemid 34163530)
2. Nowak AK, Lake RA, Kindler HL and Robinson BW: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 29: 82-96, 2002. (Pubitemid 34163539)
3. Tomek S, Emri S, Krejcy K and Manegold C: Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer 88: 167-174, 2003. (Pubitemid 36258399)
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003. (Pubitemid 46606305)
5. Takeuchi K and Ito F: Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 34: 1774-1780, 2011.
6. Benati D and Baldari CT: SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr Med Chem 15: 1154-1165, 2008. (Pubitemid 351997805)
7. Sen B and Johnson FM: Regulation of Src family kinases in human cancers. J Signal Transduct 2011: 1-14, 2011.
8. Thomas SM and Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513-609, 1997. (Pubitemid 28034534)
9. Ishizawar R and Parsons SJ: C-Src and cooperating partners in human cancer. Cancer Cell 6: 209-214, 2004. (Pubitemid 39222033)
10. Abram CL and Courteidge: Src family tyrosine kinases and growth factor signaling. Exp Cell Res 254: 1-13, 2000.
11. Roche S and Courtneidge SA: v-Yes as a transforming factor. In: Oncogenic Cytoplasmic Tyrosine Kinases. Peters G and Vousden KH (eds). Oxford University Press., Oxford, pp87-120, 1997.
12. Pena SV, Melhem MF, Meisler AI and Cartwright CA: Elevated c-Yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology 108: 117-124, 1995.
13. Han NM, Curley SA and Gallick GE: Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer Res 2: 1397-1404, 1996. (Pubitemid 26299440)
14. Kashiwagi K, Harada K, Yano Y, et al: A redox-silent analogue of tocotrienol inhibits hypoxia adaptation of lung cancer cells. Biochem Biophys Res Commun 365: 875-881, 2008. (Pubitemid 350234875)
15. Tsao AS, HeD, Saigal B, et al: Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6: 1962-1972, 2007. (Pubitemid 47052486)
16. Sancier F, Dumont A, Sirvent A, et al: Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells. Plos One 6: 1-10, 2011.
17. Kato-Stankiewicz J, Hakimi I, Zhi G, et al: Inhibitors of Ras/Raf-1 interaction identified by two hybrid screening revert Ras-dependent transformation phenotypes in human cnacer cells. Proc Natl Acad Sci USA 99: 14398-14403, 2002. (Pubitemid 35257683)
18. Kim YM, Ma H, Oehler VG, et al: The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells. Curr Cancer Drug Targets 11: 213-225, 2011.
19. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 15: 493-500, 2003.
20. Kao SC, Lee K, Armstrong NJ, et al: Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology 43: 128-132, 2011.
21. Johnson FM, Saigal B, Tran H and Donato NJ: Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 13: 4233-4244, 2007. (Pubitemid 47105988)
22. Menges CW, Chen Y, Mossman BT, et al: A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 1: 493-505, 2010.
23. Kashiwagi K, Virgona N, Harada K, et al: A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. Life Sci 84: 650-656, 2009.
24. Cadigan KM: TCFs and Wnt/β-catenin signaling: more than one way to throw the switch. Curr Top Dev Biol 98: 1-34, 2012.
25. Saini SS and Klein MA: Targeting cyclin D1 in non-small cell lung cancer and mesothelioma cells by antisense oligonucleotides. Anticancer Res 31: 3683-3690, 2011.
26. Oneyama C, Ichino T, Saito K, et al: Transforming potential of Src family kinases is limited by the cholesterol-enriched membrane microdomain. Mol Cell Biol 29: 6462-6472, 2009.